Aadi Bioscience Management
Management criteria checks 2/4
Aadi Bioscience's CEO is Dave Lennon, appointed in Oct 2023, has a tenure of 1.17 years. total yearly compensation is $2.14M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.093% of the company’s shares, worth $68.60K. The average tenure of the management team and the board of directors is 2.5 years and 3.3 years respectively.
Key information
Dave Lennon
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 7.5% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.09% |
| Management average tenure | 2.5yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop
Jul 03
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?
Jul 02Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)
May 10Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified
Mar 07Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Feb 12Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge
Dec 16Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results
Nov 10Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Oct 03Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Jun 28Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Mar 04Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors
Oct 12A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)
Sep 28Aadi Bioscience: Taking mTOR Inhibition To The Next Level
Sep 21Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Jul 06Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes
Jun 23What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today
Nov 27Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning
Nov 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$62m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$69m |
| Dec 31 2023 | US$2m | US$160k | -US$66m |
Compensation vs Market: Dave's total compensation ($USD2.14M) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Insufficient data to compare Dave's compensation with company performance.
CEO
Dave Lennon (53 yo)
1.2yrs
Tenure
US$2,135,687
Compensation
Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.2yrs | US$2.14m | 0.093% $ 68.6k | |
| CFO, Treasurer | 3.1yrs | US$1.97m | 0% $ 0 | |
| Senior VP of Legal & General Counsel | 2.8yrs | no data | no data | |
| Senior VP of Human Resources & Chief Human Resources Officer | 2.5yrs | no data | no data | |
| Chief Technical Operations Officer | 2.3yrs | no data | 0.41% $ 300.0k |
2.5yrs
Average Tenure
54yo
Average Age
Experienced Management: AADI's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.2yrs | US$2.14m | 0.093% $ 68.6k | |
| Independent Chairman of the Board | 3.3yrs | US$258.91k | 0.080% $ 59.1k | |
| Independent Director | 3.3yrs | US$240.91k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$235.91k | 0.0046% $ 3.4k | |
| Independent Director | 3.3yrs | US$227.41k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$240.91k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$345.60k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$225.41k | 0% $ 0 | |
| Director | no data | no data | no data |
3.3yrs
Average Tenure
53yo
Average Age
Experienced Board: AADI's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 23:35 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aadi Bioscience, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Burns | H.C. Wainwright & Co. |
| Roger Song | Jefferies LLC |
| Boris Peaker | TD Cowen |